Sanctuary Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Sanctuary Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$23.4K	Hold	58	–	–	0.02%	128
2024 Q3	$27K	Sell	58 -5	-8%	-$2.4K	0.02%	130
2024 Q2	$29.5K	Hold	63	–	–	0.02%	108
2024 Q1	$26.3K	Hold	63	–	–	0.02%	117
2023 Q4	$25.6K	Hold	63	–	–	0.02%	110
2023 Q3	$21.9K	Buy	63 +58	+1,160%	+$20.3K	0.02%	103
2023 Q2	$1.76K	Buy	+5	New	+$1.69K	﹤0.01%	206
2022 Q4	$1.44K	Buy	+5	New	+$1.52K	﹤0.01%	201

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sanctuary Wealth Management's VRTX Position: Q4 2024 in Review

Sanctuary Wealth Management held its Vertex Pharmaceuticals (VRTX) position steady in Q4 2024 at 58 shares worth $23.4K. The position accounts for 0.02% of the portfolio, ranked #128.

Sanctuary Wealth Management first reported a position in VRTX in Q4 2022 and has held it in 8 quarters since. The position peaked at $29.5K in Q2 2024. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

Sanctuary Wealth Management held 58 shares of Vertex Pharmaceuticals worth $23.4K as of Q4 2024.
Sanctuary Wealth Management left its Vertex Pharmaceuticals share count unchanged in Q4 2024.
Vertex Pharmaceuticals made up 0.02% of Sanctuary Wealth Management's portfolio in Q4 2024, its #128 holding.
Sanctuary Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 8 quarters since.
Sanctuary Wealth Management's Vertex Pharmaceuticals position peaked at $29.5K in Q2 2024.
1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Sanctuary Wealth Management's 13F filing for Q4 2024, filed 12 Feb 2025.